Dupilumab Tied to Fewer Exacerbations in COPD With Type 2 Inflammation
By Elana Gotkine HealthDay Reporter
TUESDAY, May 21, 2024 -- Dupilumab is associated with fewer exacerbations for patients with chronic obstructive pulmonary disease (COPD) with type 2 inflammation, according to a study published online May 20 in the New England Journal of Medicine to coincide with the American Thoracic Society 2024 International Conference, held from May 17 to 22 in San Diego.
Surya P. Bhatt, M.D., M.S.P.H., from the University of Alabama in Birmingham, and colleagues conducted a double-blind trial involving patients with COPD who had a blood eosinophil count of 300 cells/µL or higher. The participants received subcutaneous dupilumab (300 mg) or placebo every two weeks (470 and 465 patients, respectively).
Overall, 721 of the participants were included in the analysis at week 52. The researchers found that the annualized rate of moderate or severe exacerbations was 0.86 and 1.30 with dupilumab and placebo (rate ratio, 0.66). From baseline to week 12, there was an increase seen in the prebronchodilator forced expiratory volume in one second with dupilumab versus placebo (least-squares mean change, 139 versus 57 mL), with a significant least-squares mean difference of 82 and 62 mL at week 12 and week 52, respectively. The change in St. George's Respiratory Questionnaire scores from baseline to week 52 did not differ significantly between the groups. A similar incidence of adverse events was seen in the two groups.
"Our trial confirmed that add-on dupilumab treatment reduced the rate of exacerbations and increased lung function in patients with COPD with type 2 inflammation as indicated by elevated blood eosinophil counts," the authors write.
The study was funded by Sanofi and Regeneron, the manufacturers of dupilumab.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
Race-Neutral Metrics More Accurately Predict Risk in COPD
FRIDAY, May 31, 2024 -- Race-neutral metrics more accurately predict the risk for death and exacerbations in chronic obstructive pulmonary disease (COPD), according to a study...
Researchers Compare Race-Based, Race-Neutral Lung Function Equations
TUESDAY, May 21, 2024 -- The use of race-based and race-neutral equations for lung-function testing generate similarly accurate predictions of respiratory outcomes, but differ in...
Pulmonologist Intervention Beneficial for Undiagnosed Asthma, COPD
TUESDAY, May 21, 2024 -- For adults with undiagnosed asthma and chronic obstructive pulmonary disease (COPD), receipt of pulmonologist-directed treatment is associated with less...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.